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1532 Harris December 2013INVITED COMMENTARYLinda Harris, MD, Buffalo, NYDr Vartanian and colleagues have retrospectively analyzed the
outcomes of patients treated with bare metal stent (BMS) vs those
treated with stent graft (SG) in the femoral popliteal segment and
have found a higher incidence of acute limb ischemia presentations,
requiring urgent intervention with thrombolysis for limb salvage,
with SG failures. The groups were not entirely equivalent, as this
was a retrospective study.However, theBMSgroupwasmore disad-
vantaged, in general, being older, with more critical limb ischemia
(CLI), and a trend toward greater incidence of end-stage renal
disease. Also, none of the SGs extended to the popliteal artery,
whereas 11% of BMSs involved the popliteal artery.
Clearly, BMSs have limitations, with well-documented recur-
rence risks, especially with TransAtlantic Inter-Society Consensus
D lesions, leading many to search for better endovascular alterna-
tives. Some surgeons have proposed stent grafting as a better alter-
native to decrease the risk of in stent restenosis and recurrence.
Although Dr Vartanian has conﬁrmed that the SG does, indeed,
have a lower incidence of recurrent stenosis (25% vs 36%), the
key concern identiﬁed in this study is not the absolute failure
rate, but rather the mode of failure. No patients with BMS failuredeveloped acute limb ischemia, rather they reverted to their prior
status, whereas nine patients with SGs (15.5%) presented with
acute limb ischemia, with ﬁve converting from claudication at
initial presentation to CLI. Further, four of these patients required
bypass, and four had loss of runoff. The authors did not ﬁnd
a signiﬁcant difference in overall conversion to CLI from claudica-
tion, likely because of type II error with small number of patients
in each cohort.
The key concern that this study raises is the mode of failure of
the SGs and whether aggressiveness of intervention for claudica-
tion with SGs should be tempered. While certainly most vascular
surgeons today would opt for an endovascular ﬁrst approach to
claudicants, this is predicated on the perception that the endovas-
cular intervention will not increase the risk of progression or limb
loss. The use of the SG in this population should be carefully
considered, especially with smaller vessels or those patients not
able to tolerate antiplatelet therapy. SGs will have a lower rate of
recurrent stenosis, but is the lower rate of reintervention worth
the risk of acute limb ischemia with the need for emergent
thrombolysis?
